Bristol Myers Squibb’s shares experienced a decline today, likely influenced by lingering concerns surrounding the impact of generic competition on several of its key pharmaceutical products. Recent reports have highlighted the significant revenue erosion from drugs like Revlimid, Pomalyst, and Sprycel due to the entry of generics into the market. This decline in established revenue streams is a critical financial headwind, with first-quarter figures indicating substantial reductions in sales for these products. The company’s revised full-year earnings per share guidance also reflects a conservative outlook, falling below previous year’s actuals, which may contribute to investor apprehension regarding its near-term financial…